ABOLOGIX is admitted to Fondation Eclosion, the Geneva life sciences incubator

branding425
Sep 6, 2018
1 min read

Geneva, Switzerland, September 5, 2018 – Abologix has been selected to participate in the incubation program sponsored by Fondation Eclosion. As part of this program Abologix will receive business, scientific and financial support from Fondation Eclosion. The company will receive 150,000 CHF in the form of a convertible loan.

Abologix obtains funding from the KICK FUND

Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...

Successful completion of the Innosuisse Innovation Project

Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...

Nomination of product H225 as the lead preclinical candidate

Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...

ABOLOGIX is admitted to Fondation Eclosion, the Geneva life sciences incubator

Comments

Back to Top